Drug profile · INN
beclomethasone dipropionate monohydrate
VANCENASE AQ
beclomethasone dipropionate monohydrate (VANCENASE AQ) is a glucocorticoid receptor agonist. Route of administration: nasal. Current US regulatory status: approved.
Drug details — beclomethasone dipropionate monohydrate
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
beclomethasone dipropionate monohydrate (VANCENASE AQ) is a glucocorticoid receptor agonist. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is beclomethasone dipropionate monohydrate?
beclomethasone dipropionate monohydrate (VANCENASE AQ) is a glucocorticoid receptor agonist. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for beclomethasone dipropionate monohydrate?
VANCENASE AQ is a marketed brand name for beclomethasone dipropionate monohydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of beclomethasone dipropionate monohydrate?
beclomethasone dipropionate monohydrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.